Montreal, QC, Canada (June 19, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it will be participating at the following investor conferences:
Leerink Partners Private Company Connect
- Date: June 25 – 26th, 2024
- Location: Virtual
Piper Sandler 2nd Annual Virtual Obesity Day Fireside Chat
- Date: June 26th, 2024
- Time: 1:30 – 1:55PM EST
- Location: Virtual
About 35Pharma
35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment of Cardiometabolic Disease and Obesity. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta ligands while sparing beneficial homeostatic ligands.
Contact
Julia Schoelermann, VP Corporate Development, 35Pharma
info@35pharma.com
For more information, please visit www.35pharma.com
